1. Home
  2. HCAT vs PYPD Comparison

HCAT vs PYPD Comparison

Compare HCAT & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Health Catalyst Inc

HCAT

Health Catalyst Inc

HOLD

Current Price

$2.26

Market Cap

102.0M

Sector

Technology

ML Signal

HOLD

Logo PolyPid Ltd.

PYPD

PolyPid Ltd.

HOLD

Current Price

$5.38

Market Cap

85.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCAT
PYPD
Founded
2008
2008
Country
United States
Israel
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.0M
85.1M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
HCAT
PYPD
Price
$2.26
$5.38
Analyst Decision
Hold
Strong Buy
Analyst Count
10
4
Target Price
$2.53
$12.25
AVG Volume (30 Days)
1.6M
226.9K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$311,136,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.48
N/A
52 Week Low
$0.96
$3.06
52 Week High
$4.12
$5.62

Technical Indicators

Market Signals
Indicator
HCAT
PYPD
Relative Strength Index (RSI) 67.24 57.47
Support Level $2.23 $4.22
Resistance Level $2.35 $5.62
Average True Range (ATR) 0.14 0.36
MACD -0.00 0.00
Stochastic Oscillator 74.00 64.36

Price Performance

Historical Comparison
HCAT
PYPD

About HCAT Health Catalyst Inc

Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.

About PYPD PolyPid Ltd.

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Share on Social Networks: